| LBCTR2021064791 | GBT2104-131 | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises | Interventional | Recruiting | 05/05/2021 |
| LBCTR2021074831 | GBT2104-132 (C5361002) | A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises | GBT2104-132: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises | Interventional | Other | 24/06/2021 |
| LBCTR2021074838 | GBT2104-133 | An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial | An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial | Interventional | Pending | 05/07/2021 |
| LBCTR2019090195 | GBT440-007 | Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease | A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Exploratory Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease | Interventional | Complete | 19/02/2019 |
| LBCTR2019080217 | GBT440-031 | Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE) | A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease | Interventional | Complete | 16/07/2020 |
| LBCTR2019080216 | GBT440-034 | Study to Assess the Effect of Long-term Treatment With GBT440 in Participants Who Have Completed Treatment in Study GBT440-031 | An Open Label Extension Study of GBT440 Administered Orally to Patients With Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials | Interventional | Other | 27/03/2019 |
| LBCTR2020063513 | GBT440-038 | Open-Label Extension of Voxelotor | An Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials | Interventional | Pending | 12/06/2020 |
| LBCTR2021024523 | GC1801 | Phase 3 study to evaluate the efficacy and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in subjects with congenital afibrinogenaemia and severe hypofibrinogenemia | A prospective, multicenter, open-label, single-arm study to evaluate the efficacy and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in subjects with congenital afibrinogenaemia and severe hypofibrinogenemia requiring either ondemand treatment for acute bleeding or surgical prophylaxis | Interventional | Pending | 14/07/2020 |
| LBCTR2024095653 | H.pylori-2016-001 | Comparison of Two Treatment Regimens for Helicobacter pylori Eradication in Lebanon | A Randomized Prospective and Crossover Study Comparing the Eradication Rate After 10 Days of Concomitant Therapy to Bismuth Quadruple Therapy Among a Sample of the Lebanese Population | Observational | Complete | 16/09/2024 |
| LBCTR2019121361 | HD2305 | Preoperative Chlorhexidine Gluconate Bathing Could Prevent Post-obstetric and gynecologic Surgical-site Infections: A Pilot for a Randomized Controlled Trial | Preoperative Chlorhexidine Gluconate Bathing Could Prevent Post-obstetric and gynecologic Surgical-site Infections: A Pilot for a Randomized Controlled Trial | Interventional | Pending | 24/12/2019 |